Paper38332002
Drug repurposing screen identifies lonafarnib as respiratory syncytial virus fusion protein inhibitor.
Sake SM and 31 others. Nat Commun, 2024. Cited by 36 papers, by iCite.
Cite this record
ConductScience Library. Drug repurposing screen identifies lonafarnib as respiratory syncytial virus fusion protein inhibitor. Papers, record 38332002. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/38332002
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Drug repurposing screen identifies lonafarnib as respiratory syncytial virus fusion protein inhibitor.
- PubMed
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Dibenzocycloheptenes | Major topic |
| Pyridines | Major topic |
| Respiratory Syncytial Virus Infections | Major topic |
| Animals | |
| Female | |
| Mice | |
| Drug Repositioning | |
| Piperidines | |
| Viral Fusion Proteins |
Source PubMed
Grants13
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| EXC 2155 RESIST, Project 390874280 | Deutsche Forschungsgemeinschaft (German Research Foundation) | PubMed | ||
| EXC 2155 "RESIST" - Project ID 390874280 | Deutsche Forschungsgemeinschaft (German Research Foundation) | PubMed | ||
| EXC 2155 "RESIST" - Project ID 390874280 | Deutsche Forschungsgemeinschaft (German Research Foundation) | PubMed | ||
| EXC 2155 "RESIST" - Project ID 390874280 | Deutsche Forschungsgemeinschaft (German Research Foundation) | PubMed | ||
| EXC 2155 "RESIST" - Project ID 390874280 | Deutsche Forschungsgemeinschaft (German Research Foundation) | PubMed | ||
| EXC2155 RESIST_390874280 | Deutsche Forschungsgemeinschaft (German Research Foundation) | PubMed | ||
| INDIRA 11-76251-99-6/19 (ZN3437) | Niedersächsisches Ministerium für Wissenschaft und Kultur (Ministry for Science and Culture of Lower Saxony) | PubMed | ||
| OPTIS, Project ID 9B811 | Volkswagen Foundation (VolkswagenStiftung) | PubMed | ||
| OPTIS, Project ID 9B811 | Volkswagen Foundation (VolkswagenStiftung) | PubMed | ||
| OPTIS, Project ID 9B811 | Volkswagen Foundation (VolkswagenStiftung) | PubMed | ||
| OPTIS, ID9B811 | Volkswagen Foundation (VolkswagenStiftung) | PubMed | ||
| DZIF, TTU 09.719 | Deutsches Zentrum für Infektionsforschung (German Center for Infection Research) | PubMed | ||
| INDIRA 11-76251-99-6/19 (ZN3437) | Niedersächsische Ministerium für Wissenschaft und Kultur (Lower Saxony Ministry of Science and Culture) | PubMed |
Source PubMed
References62
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 27839855 | Global, regional, and national causes of under-5 mortality in 2000-15: an updated systematic analysis with implications for the Sustainable Development Goals. | Lancet | 2016 | https://conductscience.org/library/papers/27839855 | PubMed |
| 2 | 26411809 | Lower respiratory tract infection caused by respiratory syncytial virus: current management and new therapeutics. | Lancet Respir Med | 2015 | https://conductscience.org/library/papers/26411809 | PubMed |
| 3 | 34725031 | Non-Appearance of the RSV Season 2020/21 During the COVID-19 Pandemic–Prospective, Multicenter Data on the Incidence of Respiratory Syncytial Virus (RSV) Infection. | Dtsch Arztebl Int | 2021 | https://conductscience.org/library/papers/34725031 | PubMed |
| 4 | 33817612 | The impact of the lockdown and the re-opening of schools and day cares on the epidemiology of SARS-CoV-2 and other respiratory infections in children - A nationwide register study in Finland. | EClinicalMedicine | 2021 | https://conductscience.org/library/papers/33817612 | PubMed |
| 5 | 36063828 | Epidemiology of respiratory syncytial virus in children younger than 5 years in England during the COVID-19 pandemic, measured by laboratory, clinical, and syndromic surveillance: a retrospective observational study. | Lancet Infect Dis | 2023 | https://conductscience.org/library/papers/36063828 | PubMed |
| 6 | 36463892 | Decline of RSV-specific antibodies during the COVID-19 pandemic. | Lancet Infect Dis | 2023 | https://conductscience.org/library/papers/36463892 | PubMed |
| 7 | 36520324 | Preventing Respiratory Syncytial Virus in Children in France: A Narrative Review of the Importance of a Reinforced Partnership Between Parents, Healthcare Professionals, and Public Health Authorities. | Infect Dis Ther | 2023 | https://conductscience.org/library/papers/36520324 | PubMed |
| 8 | 20528472 | Palivizumab-resistant human respiratory syncytial virus infection in infancy. | Clin Infect Dis | 2010 | https://conductscience.org/library/papers/20528472 | PubMed |
| 9 | 37749081 | The road to approved vaccines for respiratory syncytial virus. | NPJ Vaccines | 2023 | https://conductscience.org/library/papers/37749081 | PubMed |
| 10 | 30411898 | State of the Art in Respiratory Syncytial Virus Drug Discovery and Development. | J Med Chem | 2019 | https://conductscience.org/library/papers/30411898 | PubMed |
| 11 | 33656652 | The Future of Respiratory Syncytial Virus Disease Prevention and Treatment. | Infect Dis Ther | 2021 | https://conductscience.org/library/papers/33656652 | PubMed |
| 12 | 34234347 | A condensate-hardening drug blocks RSV replication in vivo. | Nature | 2021 | https://conductscience.org/library/papers/34234347 | PubMed |
| 13 | 30282735 | The ReFRAME library as a comprehensive drug repurposing library and its application to the treatment of cryptosporidiosis. | Proc Natl Acad Sci U S A | 2018 | https://conductscience.org/library/papers/30282735 | PubMed |
| 14 | 32707573 | Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. | Nature | 2020 | https://conductscience.org/library/papers/32707573 | PubMed |
| 15 | 25140957 | Oral GS-5806 activity in a respiratory syncytial virus challenge study. | N Engl J Med | 2014 | https://conductscience.org/library/papers/25140957 | PubMed |
| 16 | 17576833 | RSV604, a novel inhibitor of respiratory syncytial virus replication. | Antimicrob Agents Chemother | 2007 | https://conductscience.org/library/papers/17576833 | PubMed |
| 17 | 30068272 | Farnesyl Transferase Inhibitors as Potential Anticancer Agents. | Mini Rev Med Chem | 2018 | https://conductscience.org/library/papers/30068272 | PubMed |
| 18 | 33590450 | Lonafarnib: First Approval. | Drugs | 2021 | https://conductscience.org/library/papers/33590450 | PubMed |
| 19 | 22046132 | The SARS-coronavirus-host interactome: identification of cyclophilins as target for pan-coronavirus inhibitors. | PLoS Pathog | 2011 | https://conductscience.org/library/papers/22046132 | PubMed |
| 20 | 26719246 | Identification of a Human Respiratory Syncytial Virus Cell Entry Inhibitor by Using a Novel Lentiviral Pseudotype System. | J Virol | 2015 | https://conductscience.org/library/papers/26719246 | PubMed |
Cited by27
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 36 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42963363 | Sparfloxacin reveals a host-virus dual-target antiviral scaffold against respiratory syncytial virus. | Commun Biol | 2026 | https://conductscience.org/library/papers/42963363 | PubMed |
| 42908255 | Validation of Small-Molecule Entry Inhibitors Targeting the Respiratory Syncytial Virus. | ChemMedChem | 2026 | https://conductscience.org/library/papers/42908255 | PubMed |
| 42890265 | A repurposing screen of 29 media mixtures derived from 15 commercial serum-free media products identifies potential cost reductions for industrial animal cell cultivation. | 3 Biotech | 2026 | https://conductscience.org/library/papers/42890265 | PubMed |
| 42347671 | Advances in Detection Methods for Human Respiratory Syncytial Virus Neutralizing Antibodies. | Vaccines (Basel) | 2026 | https://conductscience.org/library/papers/42347671 | PubMed |
| 42210414 | Renaissance of farnesyltransferase inhibitors in cancer. | J Transl Med | 2026 | https://conductscience.org/library/papers/42210414 | PubMed |
| 42197515 | Structural Advances in Respiratory Syncytial Virus: Implications for Vaccine and Antiviral Development. | Microorganisms | 2026 | https://conductscience.org/library/papers/42197515 | PubMed |
| 42007710 | Catching our breath: development of interventions and therapies for respiratory syncytial virus. | Microbiol Mol Biol Rev | 2026 | https://conductscience.org/library/papers/42007710 | PubMed |
| 41770611 | FDA-approved IMPDH inhibitors synergize with ribavirin to inhibit respiratory syncytial virus by interfering with purine de novo synthesis. | Emerg Microbes Infect | 2026 | https://conductscience.org/library/papers/41770611 | PubMed |
| 41576151 | Molecular mechanism of ziresovir targeting the fusion glycoprotein of respiratory syncytial virus. | PLoS Pathog | 2026 | https://conductscience.org/library/papers/41576151 | PubMed |
| 41472282 | Repurposing FDA-Approved Drugs as Hendra Virus RNA-Dependent RNA Polymerase Inhibitors: A Comprehensive Computational Drug Discovery Approach. | Viruses | 2025 | https://conductscience.org/library/papers/41472282 | PubMed |
| 41413286 | β2-adrenergic signaling controls neonatal respiratory syncytial virus infection by promoting viral clearance and airway protection. | Nat Commun | 2025 | https://conductscience.org/library/papers/41413286 | PubMed |
| 41364004 | Molecular mechanism of resistance to lonafarnib conferred by mutations in the cysteine-rich region of respiratory syncytial virus fusion glycoprotein and discovery of a lonafarnib-derived antiviral PROTAC. | J Virol | 2026 | https://conductscience.org/library/papers/41364004 | PubMed |
| 41327890 | Mucin-Inspired Filamentous Sulfated Copolymers Effectively Inhibit Human Respiratory Syncytial Virus (hRSV) Infectivity. | Adv Sci (Weinh) | 2026 | https://conductscience.org/library/papers/41327890 | PubMed |
| 41030913 | Molecular and Cellular Mechanisms of Respiratory Syncytial Viral Infection: Its Implications for Prophylactic and Therapeutic Pharmaceuticals. | MedComm (2020) | 2025 | https://conductscience.org/library/papers/41030913 | PubMed |
| 41026531 | High-throughput screens identify genotype-specific therapeutics for channelopathies. | JCI Insight | 2025 | https://conductscience.org/library/papers/41026531 | PubMed |
| 40848680 | Status of advanced respiratory syncytial virus antiviral therapeutics 2025. | Curr Opin Virol | 2025 | https://conductscience.org/library/papers/40848680 | PubMed |
| 40749064 | A pan-respiratory virus attachment inhibitor with high potency in human airway models and in vivo. | Sci Adv | 2025 | https://conductscience.org/library/papers/40749064 | PubMed |
| 40486844 | Advances in development of antiviral strategies against respiratory syncytial virus. | Acta Pharm Sin B | 2025 | https://conductscience.org/library/papers/40486844 | PubMed |
| 40316857 | Cangrelor and AVN-944 as repurposable candidate drugs for hMPV: analysis entailed by AI-driven in silico approach. | Mol Divers | 2025 | https://conductscience.org/library/papers/40316857 | PubMed |
| 40016246 | Rational design of phytovirucide inhibiting nucleocapsid protein aggregation in tomato spotted wilt virus. | Nat Commun | 2025 | https://conductscience.org/library/papers/40016246 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| HSP90AA1 | 3320 | PubTator's text mining | https://conductscience.org/library/genes/3320 |
Source NCBI Gene
Data2
The data bank entries PubMed's record names. Trial numbers are under Trials.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/38332002
GET https://conductscience.org/api/papers/v1/38332002/authors?page=2